To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

September 13, 2019___

Today's Rundown

Featured Story

Biogen, Eisai throw out remaining Alzheimer's BACE hope

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

Top Stories

Amgen shares hit after analysts expose buried FDA trial halt

Amgen Thursday posted what appeared to be a fairly innocuous update about its drug Kyprolis and other pipeline assets, but a deeper read turned up a nasty surprise.

Ritter's microbiome modulator fails lactose intolerance phase 3 

A phase 3 trial of Ritter Pharmaceuticals’ lactose intolerance prospect RP-G28 has missed its primary endpoint. The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.

[Sponsored] What Makes an Oncology Clinical Trial Site Stand Out from the Competition?

Patients want the best cancer therapies, and sites that enable clinical trials are the ones that can access those new drugs faster. Here’s how

Celgene's phase 3 AML test chalks up a win

A phase 3 trial of Celgene’s acute myeloid leukemia maintenance therapy CC-486 has met its primary endpoint. Patients who took the cytidine nucleoside analog lived longer than their peers on placebo.

Pillar ponies up for Petri, Boston's new accelerator for fledgling biotechs

Boston-based Pillar is bankrolling a new accelerator for budding biotechs. Named Petri, the accelerator aims to serve a group left behind by life sciences- and health IT-focused VC firms—startups at the “frontier of biology and engineering.”

EuroBiotech Report—Sanofi pays to scrap deal, BioNTech IPO, GSK takeover, Roche and 4BIO

In this week's EuroBiotech Report, Sanofi pays $260 million to can Lexicon deal, BioNTech files for IPO and GSK buys celiac startup. 

FiercePharmaAsia—BeiGene’s short attack; Sumitomo-Roivant deal; Roche-JHL settlement

BeiGene called allegations that it inflated drug sales numbers by 60% "wild speculations." Sumitomo Dainippon is paying $3 billion up front to pick up five of the "vant" biotechs. Likely to focus its legal power against individuals who allegedly stole trade secrets, Genentech has settled with JHL Biotech. And more.

Chutes & Ladders—Bayer trims 2 execs in corporate reshuffling

Bayer dumps two execs in corporate reshuffle; Coles to take over at Bayer spinoff Cerevel; Sanofi vet Jensen wins CMO spot at Vifor.

Enrollment Showcase

BioImmersion: Biotech for the Non-Scientist

BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today!

Resources

[Whitepaper] How Can You Avoid the Fallout From Incompatibility Between Your API and Its Formulation?

Avoid potential risks to the patient as well as costly interruptions during development.

[Article] Why Market Leaders Outsource IT Requirements For A Competitive Edge

Find out how outsourcing your IT requirements enhances the bottom line while creating strategic advantage.

[Whitepaper] From Complex to Controlled: Advanced Data Management Strategies for Advanced Therapies

Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success.

[Whitepaper] Advancing Healthcare Market Intelligence With Smart Search Technology

AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy.

[Whitepaper] What's Your Lab Trying to Tell You? Listen with Connected IoT Sensors

Your lab is talking to you, are you listening?

[Whitepaper] Prevent the Real World From Derailing Your Clinical Trial: Focus on Protocol Design

Want to be sure your renal research protocol design is fit for the real world?

[Whitepaper] Optimizing Operations in Multiproduct Pharma Manufacturing Facilities

Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities?

[Report] Future of clinical trials: From real-time data to algorithmic trials

Clinical trials are one of the pharma industry’s most painful and costly processes. Read how technology could transform the trial process from nine years to a matter of hours.

[Whitepaper] Considerations and Options for Prefilled Syringes

Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe.

[Article] Sales Compensation: 7 Trending Topics

From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation.

[Whitepaper] The Supply Chain Planning Cure for Everything from Product Expirations to Patent Cliffs

Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events